Dr. Guglietta: Yes. So, it's exactly the challenge. And what we are actually seeing is that at the moment, especially for ...

The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...

Colorectal cancer is the second leading cause of cancer death in the U.S., with over 152,000 cases and nearly 53,000 deaths ...

A little-known mouse protein disrupts cancer-causing chemical changes to genes associated with human colorectal cancer cells ...

It’s worth thinking about when investigating the increase in colon cancer in young people.

Through simulation analysis, the team systematically identified master molecular switches that induce normal cell differentiation. When these switches were applied to colon cancer cells ...

When these switches were applied to colon cancer cells, the cancer cells reverted to a normal-like state, a result confirmed through molecular and cellular experiments as well as animal studies.

Table 1. CRC Key Targets for CAR-T Cell Therapy and Their Associated Clinical Trials CDH17 CHM-2101 The United States Phase I/II CAR-T therapy targeting CDH17 in advanced colorectal, gastric, and ...

These regulators are known as MYB, HDAC2, and FOXA2 and when they were suppressed in colon cancer cells, the cells switched back to a normal-like state, removing the cancer threat without ...

A research team led by Professor Kwang-Hyun Cho from the Department of Bio and Brain Engineering has developed a pioneering technique to treat colon cancer. Instead of killing cancer cells ...